Skip to content

GLP-1 microdosing: what it means and what the labels say

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

“GLP-1 microdosing” usually means taking semaglutide or tirzepatide at doses smaller than the approved maintenance doses, or staying on a starting dose for a long time. It is a marketing term, not a medical one: none of the FDA labels for Wegovy, Zepbound or Foundayo contains a microdose schedule. What the labels do contain are low starting doses, slow steps up, and room for a lower dose when side effects get in the way.

What the labels actually say about low doses

Every approved weight-loss GLP-1 starts low and climbs:

Medicine Starting dose Where the label says to go
Wegovy injection 0.25 mg a week for weeks 1 to 4 [1] 1.7 mg or 2.4 mg a week for maintenance [2]
Wegovy pill 1.5 mg a day for days 1 to 30 [4] 25 mg a day from day 91 [4]
Zepbound 2.5 mg a week for 4 weeks [5] 5 mg, 10 mg or 15 mg a week [7]
Foundayo 0.8 mg a day for at least 30 days [9] [10] 2.5 mg, then 5.5 mg, then higher steps if needed [10] [11] [12]

Two details matter for anyone reading microdosing ads:

  • Starting doses are not maintenance doses. Zepbound’s label says the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose [6]. Wegovy’s maintenance dose for adult weight loss is 1.7 mg or 2.4 mg [2], well above its 0.25 mg start.
  • The labels already allow a gentler path. If a Wegovy step is not tolerated, the label says to consider waiting 4 weeks before going up [3]. Zepbound’s label says to weigh response and tolerability when picking a maintenance dose, and to consider a lower one if needed [8]. Foundayo moves up only after at least 30 days at each step, based on response and tolerability [12].

So a slower climb, or settling on a lower approved maintenance dose, can happen inside the label with your prescriber. Staying indefinitely on a starting dose, or taking fractions of a dose that no brand-name pen or pill supplies, is outside it.

Where microdoses come from

Brand-name products come only in the strengths on their labels: Zepbound pens and vials from 2.5 mg to 15 mg [19], for example, and Wegovy tablets of 1.5 mg, 4 mg, 9 mg and 25 mg [20]. A dose below or between those strengths is not an approved product, so if a plan offers one, ask whether the medicine is compounded. Compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness or quality [16], and the FDA says they should be used only when an approved drug cannot meet a patient’s medical needs [17].

The FDA’s dosing-error reports show why small doses from vials are easy to get wrong. Patients were told to draw doses as small as 5 units, or 0.05 mL, on an insulin syringe [15], and some drew 50 units instead of 5 [18]. The FDA has also received adverse event reports tied to compounded semaglutide or tirzepatide prescribed beyond label doses, including faster increases [13], and it tells prescribers to take care with compounded doses and titration schedules [14]. Our page on compounded GLP-1 doses covers the unit problem in detail.

What to ask your prescriber

  • If side effects are the worry, ask whether a slower climb or a lower approved maintenance dose fits you. Both are described in the labels above.
  • If you are offered a “microdose” plan, ask what exact medicine it is, whether it is FDA-approved or compounded, what the dose is in milligrams, and how that compares with the label.
  • Do not split, dilute or re-measure a brand-name product to make your own smaller doses.

For every approved dose of all five brand-name GLP-1s, see GLP-1 dosing compared. Prices for the approved starting doses are in our price table.

Sources

  1. Starting Dosage 1 through 4 0.25 mg Dosage Escalation 5 through 8 0.5 mg 9 through 12 1 mg 13 through 16 1.7 mg Maintenance Dosage 17 and onward See the indication below for the recommended maintenance dosage(s) dailymed.nlm.nih.gov, read Sep 27, 2026.
  2. The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly. dailymed.nlm.nih.gov, read Sep 27, 2026.
  3. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. dailymed.nlm.nih.gov, read Sep 27, 2026.
  4. Starting Dosage 1 through 30 1.5 mg Dosage Escalation 31 through 60 4 mg 61 through 90 9 mg Maintenance Dosage 91 and onward 25 mg dailymed.nlm.nih.gov, read Sep 27, 2026.
  5. The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. dailymed.nlm.nih.gov, read Sep 27, 2026.
  6. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. dailymed.nlm.nih.gov, read Sep 27, 2026.
  7. Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. (2.2) dailymed.nlm.nih.gov, read Sep 27, 2026.
  8. Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. dailymed.nlm.nih.gov, read Sep 27, 2026.
  9. The starting dosage is 0.8 mg orally once daily. dailymed.nlm.nih.gov, read Sep 27, 2026.
  10. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily. dailymed.nlm.nih.gov, read Sep 27, 2026.
  11. After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily. dailymed.nlm.nih.gov, read Sep 27, 2026.
  12. The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. dailymed.nlm.nih.gov, read Sep 27, 2026.
  13. Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label. This could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule). fda.gov, read Sep 27, 2026.
  14. Health care providers should be vigilant when prescribing compounded semaglutide or tirzepatide products and determining appropriate doses and titration and dosing schedules for patients. fda.gov, read Sep 27, 2026.
  15. In several reports, patients were instructed to use a U-100 (1 milliliter) insulin syringe to draw small doses, such as a 5-unit (0.05 milliliter) dose, from a multiple-dose vial. fda.gov, read Sep 27, 2026.
  16. However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. fda.gov, read Sep 27, 2026.
  17. Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. fda.gov, read Sep 27, 2026.
  18. As depicted in the figure below, these patients were directed to administer 5 units from a vial. However, these patients mistakenly administered 50 units instead. fda.gov, read Sep 27, 2026.
  19. Single-dose pen or single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, or 15 mg/0.5 mL (3) dailymed.nlm.nih.gov, read Sep 27, 2026.
  20. Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg (3) dailymed.nlm.nih.gov, read Sep 27, 2026.

This page reports what official sources say; it is not medical advice. Medical disclaimer.